+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

  • ID: 4533505
  • Report
  • April 2020
  • Region: Global
  • 54 Pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2017, there were approximately 19,950 incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and forecasts that number to increase to 23,880 incident cases by 2026.
  • It is estimated that the majority of diagnosed cases were in males in 2017.
  • The incidence of PTCL is highest among older individuals aged 60+ years. The approved drugs in the PTCL space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.
  • The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II. Therapies in development for PTCL focus on a wide variety of targets. These therapies are administered via the oral and intravenous routes.
  • High-impact upcoming events for drugs in the PTCL space comprise topline Phase II trial results for Zinapar and IPH4102, and an expected supplemental CHMP opinion for Adcetris.
  • The overall likelihood of approval of a Phase I hematologic asset is 10%, and the average probability a drug advances from Phase III is 59.6%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
  • There have been 16 licensing and asset acquisition deals involving PTCL drugs during 2015-20. The $327.5m license and supply agreement signed in 2019 between Rigel Pharmaceuticals and Grifols, to commercialize fostamatinib disodium hexahydrate in all potential indications, was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for PTCL have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.
  • The US has a substantial lead in the number of PTCL clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the PTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for PTCL, with 11 trials.
  • Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for PTCL, followed by Takeda
Note: Product cover images may vary from those shown
2 of 2
Overview

Key Takeaways

Disease Background
  • PTCL subtypes
Treatment

Epidemiology

Marketed Drugs

Pipeline Drugs

Recent Events and Analyst Opinion
  • Tipifarnib (Oncology) for PTCL (December 8, 2019)
  • Cerdulatinib for PTCL (December 8, 2019)
  • Copiktra for PTCL (December 7, 2019)
  • Copiktra for PTCL (July 25, 2019)
  • Sintilimab for PTCL (May 15, 2019)
  • Copiktra for PTCL (March 6, 2019)
  • Multiple Drugs for PTCL (January 17, 2019)
  • Copiktra for PTCL (December 3, 2018)
  • Tipifarnib (Oncology) for PTCL (December 2, 2018)
  • Campath for PTCL (November 20, 2018)
  • Adcetris for PTCL (October 1, 2018)
Key Upcoming Events

Probability of Success

Licensing and Asset Acquisition Deals
  • Meiji Gains Asia Rights To HUYA’s Lymphoma Candidate
  • Ono Licenses Rafael’s Novel Chemo-Sensitizing Agent For Asia
Parent Patents

Revenue Opportunity

Clinical Trial Landscape
  • Sponsors by status
  • Sponsors by phase
Bibliography
  • Prescription information
Appendix

List of Figures
Figure 1: Trends in incident cases of PTCL, 2017–26
Figure 2: Incident cases of PTCL, by age, 2017
Figure 3: Overview of pipeline drugs for PTCL in the US
Figure 4: Pipeline drugs for PTCL, by company
Figure 5: Pipeline drugs for PTCL, by drug type
Figure 6: Pipeline drugs for PTCL, by classification
Figure 7: Cerdulatinib for PTCL (December 8, 2019): Phase I/IIa - Two Part Dose Escalation
Figure 8: Sintilimab for PTCL (May 15, 2019): Phase II - ORIENT-4
Figure 9: Copiktra for PTCL (December 3, 2018): Phase I - w/Romidepsin or Bortezomib (TCLs) (MSKCC)
Figure 10: Tipifarnib (Oncology) for PTCL (December 2, 2018): Phase II - 002
Figure 11: Adcetris for PTCL (October 1, 2018): Phase III - ECHELON-2
Figure 12: Key upcoming events in PTCL
Figure 13: Probability of success in the PTCL pipeline
Figure 14: Licensing and asset acquisition deals in PTCL, 2015–20
Figure 15: Parent patents in PTCL
Figure 16: Clinical trials in PTCL
Figure 17: Top 10 drugs for clinical trials in PTCL
Figure 18: Top 10 companies for clinical trials in PTCL
Figure 19: Trial locations in PTCL
Figure 20: PTCL trials status
Figure 21: PTCL trials sponsors, by phase

List of Tables
Table 1: Incident cases of PTCL, 2017–26
Table 2: Incident cases of PTCL, by gender, 2017
Table 3: Marketed drugs for PTCL
Table 4: Pipeline drugs for PTCL in the US
Table 5: Tipifarnib (Oncology) for PTCL (December 8, 2019)
Table 6: Cerdulatinib for PTCL (December 8, 2019)
Table 7: Copiktra for PTCL (December 7, 2019)
Table 8: Copiktra for PTCL (July 25, 2019)
Table 9: Sintilimab for PTCL (May 15, 2019)
Table 10: Copiktra for PTCL (March 6, 2019)
Table 11: Multiple Drugs for PTCL (January 17, 2019)
Table 12: Copiktra for PTCL (December 3, 2018)
Table 13: Tipifarnib (Oncology) for PTCL (December 2, 2018)
Table 14: Campath for PTCL (November 20, 2018)
Table 15: Adcetris for PTCL (October 1, 2018)
Table 16: Historical global sales, by drug ($m), 2014–18
Table 17: Forecasted global sales, by drug ($m), 2020–24
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll